Physiomics Expects Annual Loss To Be "Materially Reduced"
LONDON (Alliance News) - Physiomics PLC said Thursday it is trading "ahead of market expectations" for its financial year to the end of June.The company, which provides technology
Read moreFri, 28th Jun 2019 10:56
LONDON (Alliance News) - Physiomics PLC said Thursday it is trading "ahead of market expectations" for its financial year to the end of June.The company, which provides technology
Read moreLONDON (Alliance News) - Physiomics PLC on Wednesday said that it raised GBP525,000 through share placing to grow the business and expand its client base.The biotechnology company issued at
Read moreLONDON (Alliance News) - Physiomics PLC said Wednesday it has been awarded a new Innovate UK Grant worth GBP68,000 for a prostate cancer -
Read moreLONDON (Alliance News) - Physiomics PLC said Monday it has successfully completed the Innovate UK grant cancer treatment project, receiving in funding the
Read more(ShareCast News) - Physiomics announced on Wednesday that it is making good progress towards the strategic objectives announced in its most recent full year results, posted on 27 October 2016. The AIM-traded firm announced an initial payment by Sareum on 5 December, for modelling carried out by the
Read more(ShareCast News) - Systems biology company Physiomics confirmed on Friday that is has been awarded the Innovate UK grant as part of its Biomedical Catalyst 2016 Feasibility Study Competition that was the subject of a provisional announcement on 22 November. The AIM-traded firm said the proposed proj
Read more(ShareCast News) - AIM listed Physiomics has called off its BioMoti acquisition after investors instead backed plans to develop its modelling and simulation business with a £555,000 discounted fundraising. Physiomics, which develops software to help drug companies predict and understand cancer drug
Read more(ShareCast News) - Physiomics had a new man at the helm on Monday, confirming Dr James Millen was taking the reins as CEO with immediate effect. The AIM-traded company said Millen, known as Jim, brought experience of drug development and licensing deals in global pharmaceutical companies with him.
Read more